Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.

Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.

The non-receptor tyrosine kinase JAK2 is implicated in a group of myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. JAK2-selective inhibitors are currently being evaluated in clinical trials. Data from drug-resistant chronic myeloid leuke...

Full description

Bibliographic Details
Main Authors: Michael R Marit, Manprit Chohan, Natasha Matthew, Kai Huang, Douglas A Kuntz, David R Rose, Dwayne L Barber
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3420867?pdf=render

Internet

http://europepmc.org/articles/PMC3420867?pdf=render

Similar Items